{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T06:44:29Z","timestamp":1777531469635,"version":"3.51.4"},"reference-count":46,"publisher":"Archives of Pathology and Laboratory Medicine","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,9]]},"abstract":"<jats:p>\n                    <jats:italic>Context.\u2014<\/jats:italic>\n                    Although bone marrow (BM) karyotyping has been the standard in monitoring patients with chronic myeloid leukemia, peripheral blood (PB) monitoring methods may be more convenient.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:italic>Objective.\u2014<\/jats:italic>\n                    To conduct post hoc analyses of the Rationale and Insight for Gleevec High-Dose Therapy study to evaluate correlations between results of cytogenetic testing and molecular monitoring from BM and PB during the first 18 months of high-dose imatinib therapy, and between early and late molecular responses.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:italic>Design.\u2014<\/jats:italic>\n                    Newly diagnosed patients with chronic-phase chronic myeloid leukemia received imatinib 400 mg twice daily and were monitored quarterly for up to 18 months. Cytogenetic testing was performed by karyotyping using BM or by fluorescence in situ hybridization using PB. Molecular testing was performed by quantitative reverse transcriptase polymerase chain reaction using BM and PB.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:italic>Results.\u2014<\/jats:italic>\n                    Significant pairwise correlations were found between results obtained by karyotyping, fluorescence in situ hybridization, and quantitative reverse transcriptase polymerase chain reaction using PB or BM (all pairwise correlations &gt;0.8;\n                    <jats:italic>P<\/jats:italic>\n                    &lt; .001). At 12 months, cytogenetic response by karyotyping correlated well with response by fluorescence in situ hybridization. A median 2.579-log reduction in\n                    <jats:italic>BCR-ABL1<\/jats:italic>\n                    level from a standardized baseline correlated with fluorescence in situ hybridization\u2013negative status. Patients with greater than 2-log reduction in\n                    <jats:italic>BCR-ABL1<\/jats:italic>\n                    level at 3, 6, and 9 months were more likely to achieve major molecular response at 18 months than those with 2-log reduction or less.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:italic>Conclusions.\u2014<\/jats:italic>\n                    Our findings support the feasibility of molecular monitoring using PB and suggest that molecular monitoring conducted at a single reliable reference laboratory can adequately track response without invasive BM testing. Our findings are consistent with other work indicating that early response to imatinib predicts favorable long-term outcome.\n                  <\/jats:p>","DOI":"10.5858\/arpa.2013-0584-oa","type":"journal-article","created":{"date-parts":[[2013,12,5]],"date-time":"2013-12-05T12:58:13Z","timestamp":1386248293000},"page":"1186-1192","source":"Crossref","is-referenced-by-count":12,"title":["Correlations Between Cytogenetic and Molecular Monitoring Among Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase: Post Hoc Analyses of the Rationale and Insight for Gleevec High-Dose Therapy Study"],"prefix":"10.5858","volume":"138","author":[{"given":"Luke P.","family":"Akard","sequence":"first","affiliation":[{"name":"From the Indiana Blood and Marrow Transplantation, Stem Cell Transplantation Program, St. Francis Hospital and Health Centers, Indianapolis, Indiana (Dr Akard); the Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston (Dr Cortes); the Departments of Oncology\/Hematopathology and Research and Development, NeoGenomics Laboratories, Irvine, California (Dr Albitar); the Division of Leukemia, John Theurer Cancer Center at Hackensack University Medical Center, Hackensack..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge E.","family":"Cortes","sequence":"additional","affiliation":[{"name":"From the Indiana Blood and Marrow Transplantation, Stem Cell Transplantation Program, St. Francis Hospital and Health Centers, Indianapolis, Indiana (Dr Akard); the Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston (Dr Cortes); the Departments of Oncology\/Hematopathology and Research and Development, NeoGenomics Laboratories, Irvine, California (Dr Albitar); the Division of Leukemia, John Theurer Cancer Center at Hackensack University Medical Center, Hackensack..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maher","family":"Albitar","sequence":"additional","affiliation":[{"name":"From the Indiana Blood and Marrow Transplantation, Stem Cell Transplantation Program, St. Francis Hospital and Health Centers, Indianapolis, Indiana (Dr Akard); the Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston (Dr Cortes); the Departments of Oncology\/Hematopathology and Research and Development, NeoGenomics Laboratories, Irvine, California (Dr Albitar); the Division of Leukemia, John Theurer Cancer Center at Hackensack University Medical Center, Hackensack..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart L.","family":"Goldberg","sequence":"additional","affiliation":[{"name":"From the Indiana Blood and Marrow Transplantation, Stem Cell Transplantation Program, St. Francis Hospital and Health Centers, Indianapolis, Indiana (Dr Akard); the Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston (Dr Cortes); the Departments of Oncology\/Hematopathology and Research and Development, NeoGenomics Laboratories, Irvine, California (Dr Albitar); the Division of Leukemia, John Theurer Cancer Center at Hackensack University Medical Center, Hackensack..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ghulam","family":"Warsi","sequence":"additional","affiliation":[{"name":"From the Indiana Blood and Marrow Transplantation, Stem Cell Transplantation Program, St. Francis Hospital and Health Centers, Indianapolis, Indiana (Dr Akard); the Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston (Dr Cortes); the Departments of Oncology\/Hematopathology and Research and Development, NeoGenomics Laboratories, Irvine, California (Dr Albitar); the Division of Leukemia, John Theurer Cancer Center at Hackensack University Medical Center, Hackensack..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meir","family":"Wetzler","sequence":"additional","affiliation":[{"name":"From the Indiana Blood and Marrow Transplantation, Stem Cell Transplantation Program, St. Francis Hospital and Health Centers, Indianapolis, Indiana (Dr Akard); the Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston (Dr Cortes); the Departments of Oncology\/Hematopathology and Research and Development, NeoGenomics Laboratories, Irvine, California (Dr Albitar); the Division of Leukemia, John Theurer Cancer Center at Hackensack University Medical Center, Hackensack..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Solveig G.","family":"Ericson","sequence":"additional","affiliation":[{"name":"From the Indiana Blood and Marrow Transplantation, Stem Cell Transplantation Program, St. Francis Hospital and Health Centers, Indianapolis, Indiana (Dr Akard); the Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston (Dr Cortes); the Departments of Oncology\/Hematopathology and Research and Development, NeoGenomics Laboratories, Irvine, California (Dr Albitar); the Division of Leukemia, John Theurer Cancer Center at Hackensack University Medical Center, Hackensack..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerald P.","family":"Radich","sequence":"additional","affiliation":[{"name":"From the Indiana Blood and Marrow Transplantation, Stem Cell Transplantation Program, St. Francis Hospital and Health Centers, Indianapolis, Indiana (Dr Akard); the Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston (Dr Cortes); the Departments of Oncology\/Hematopathology and Research and Development, NeoGenomics Laboratories, Irvine, California (Dr Albitar); the Division of Leukemia, John Theurer Cancer Center at Hackensack University Medical Center, Hackensack..."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3906","reference":[{"key":"i1543-2165-138-9-1186-b01","series-title":"NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia. Version 1","year":"2014","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia. Version 1. 2014. http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cml.pdf. Accessed September 25, 2013."},{"key":"i1543-2165-138-9-1186-b02","series-title":"J Natl Cancer Inst","first-page":"85","article-title":"Chromosome studies on normal and leukemic human leukocytes","volume":"25","author":"Nowell\n              PC,","year":"1960","unstructured":"Nowell\n              PC, \n            \n              Hungerford\n              DA. \n          \n          Chromosome studies on normal and leukemic human leukocytes. J Natl Cancer Inst. 1960;25:85\u2013109."},{"key":"i1543-2165-138-9-1186-b03","series-title":"Gleevec (imatinib mesylate) [US prescribing information]","year":"2012","unstructured":"Gleevec (imatinib mesylate) [US prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2012."},{"key":"i1543-2165-138-9-1186-b04","series-title":"Tasigna (nilotinib) [US prescribing information]","year":"2012","unstructured":"Tasigna (nilotinib) [US prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2012."},{"key":"i1543-2165-138-9-1186-b05","series-title":"Sprycel (dasatinib) [US prescribing information]","year":"2011","unstructured":"Sprycel (dasatinib) [US prescribing information]. Princeton, NJ: Bristol Meyers Squibb Company; 2011."},{"key":"i1543-2165-138-9-1186-b06","series-title":"Bosulif (bosutinib) [prescribing information]","year":"2012","unstructured":"Bosulif (bosutinib) [prescribing information]. New York, NY: Pfizer Labs; 2012."},{"key":"i1543-2165-138-9-1186-b07","series-title":"Iclusig (ponatinib) [prescribing information]","year":"2012","unstructured":"Iclusig (ponatinib) [prescribing information]. Cambridge, MA: ARIAD Pharmaceuticals, Inc; 2012."},{"issue":"12","key":"i1543-2165-138-9-1186-b08","series-title":"Leukemia","first-page":"2401","article-title":"Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase","volume":"17","author":"Branford\n              S,","year":"2003","unstructured":"Branford\n              S, \n            \n              Rudzki\n              Z, \n            \n              Harper\n              A, \n            et al\n          . Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Leukemia. 2003;17(12):2401\u20132409."},{"issue":"21","key":"i1543-2165-138-9-1186-b09","series-title":"Blood (ASH Annu Meet Abstr)","first-page":"69","article-title":"Assessment of early molecular response as a predictor of long-term clinical outcomes in the phase 3 BELA study","volume":"120","author":"Brummendorf\n              TH,","year":"2012","unstructured":"Brummendorf\n              TH, \n            \n              Kantarjian\n              HM, \n            \n              Gambacorti-Passerini\n              C, \n            et al\n          . Assessment of early molecular response as a predictor of long-term clinical outcomes in the phase 3 BELA study. Blood (ASH Annu Meet Abstr). 2012;120(21):69."},{"issue":"9","key":"i1543-2165-138-9-1186-b10","series-title":"Leukemia","first-page":"2096","article-title":"Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)","volume":"26","author":"Hanfstein\n              B,","year":"2012","unstructured":"Hanfstein\n              B, \n            \n              Muller\n              MC, \n            \n              Hehlmann\n              R, \n            et al\n          . Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia. 2012;26(9):2096\u20132102."},{"issue":"21","key":"i1543-2165-138-9-1186-b11","series-title":"Blood (ASH Annu Meet Abstr)","first-page":"167","article-title":"Outcome of patients with chronic myeloid leukemia in chronic phase (CML-CP) based on early molecular response and factors associated with early response: 4-year follow-up data from ENESTND (Evaluating Nilotinib Efficacy and Safety in Clinical Trials Newly Diagnosed Patients)","volume":"120","author":"Hochhaus\n              A,","year":"2012","unstructured":"Hochhaus\n              A, \n            \n              Hughes\n              TP, \n            \n              Saglio\n              G, \n            et al\n          . Outcome of patients with chronic myeloid leukemia in chronic phase (CML-CP) based on early molecular response and factors associated with early response: 4-year follow-up data from ENESTND (Evaluating Nilotinib Efficacy and Safety in Clinical Trials Newly Diagnosed Patients). Blood (ASH Annu Meet Abstr). 2012;120(21):167."},{"issue":"2","key":"i1543-2165-138-9-1186-b12","series-title":"Blood","first-page":"291","article-title":"Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib","volume":"120","author":"Marin\n              D,","year":"2012","unstructured":"Marin\n              D, \n            \n              Hedgley\n              C, \n            \n              Clark\n              RE, \n            et al\n          . Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib. Blood. 2012;120(2):291\u2013294."},{"issue":"3","key":"i1543-2165-138-9-1186-b13","series-title":"J Clin Oncol","first-page":"232","article-title":"Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors","volume":"30","author":"Marin\n              D,","year":"2012","unstructured":"Marin\n              D, \n            \n              Ibrahim\n              AR, \n            \n              Lucas\n              C, \n            et al\n          . Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol. 2012;30(3):232\u2013238."},{"issue":"6","key":"i1543-2165-138-9-1186-b14","series-title":"Blood","first-page":"872","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani\n              M,","year":"2013","unstructured":"Baccarani\n              M, \n            \n              Deininger\n              MW, \n            \n              Rosti\n              G, \n            et al\n          . European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122(6):872\u2013884."},{"issue":"7","key":"i1543-2165-138-9-1186-b15","series-title":"J Clin Oncol","first-page":"1533","article-title":"Fluorescence in situ hybridization on peripheral-blood specimens is a reliable method to evaluate cytogenetic response in chronic myeloid leukemia","volume":"18","author":"Le Gouill\n              S,","year":"2000","unstructured":"Le Gouill\n              S, \n            \n              Talmant\n              P, \n            \n              Milpied\n              N, \n            et al\n          . Fluorescence in situ hybridization on peripheral-blood specimens is a reliable method to evaluate cytogenetic response in chronic myeloid leukemia. J Clin Oncol. 2000;18(7):1533\u20131538."},{"issue":"2","key":"i1543-2165-138-9-1186-b16","series-title":"Cancer Genet Cytogenet","first-page":"79","article-title":"Correlation of three methods of measuring cytogenetic response in chronic myelocytic leukemia","volume":"137","author":"Lesser\n              ML,","year":"2002","unstructured":"Lesser\n              ML, \n            \n              Dewald\n              GW, \n            \n              Sison\n              CP, \n            \n              Silver\n              RT. \n          \n          Correlation of three methods of measuring cytogenetic response in chronic myelocytic leukemia. Cancer Genet Cytogenet. 2002;137(2):79\u201384."},{"issue":"6","key":"i1543-2165-138-9-1186-b17","series-title":"Cancer","first-page":"1245","article-title":"Peripheral blood monitoring of chronic myeloid leukemia during treatment with imatinib, second-line agents, and beyond","volume":"117","author":"Lima\n              L,","year":"2011","unstructured":"Lima\n              L, \n            \n              Bernal-Mizrachi\n              L, \n            \n              Saxe\n              D, \n            et al\n          . Peripheral blood monitoring of chronic myeloid leukemia during treatment with imatinib, second-line agents, and beyond. Cancer. 2011;117(6):1245\u20131252."},{"issue":"4","key":"i1543-2165-138-9-1186-b18","series-title":"Blood","first-page":"1549","article-title":"Quantification of residual disease in chronic myelogenous leukemia patients on interferon-alpha therapy by competitive polymerase chain reaction","volume":"87","author":"Hochhaus\n              A,","year":"1996","unstructured":"Hochhaus\n              A, \n            \n              Lin\n              F, \n            \n              Reiter\n              A, \n            et al\n          . Quantification of residual disease in chronic myelogenous leukemia patients on interferon-alpha therapy by competitive polymerase chain reaction. Blood. 1996;87(4):1549\u20131555."},{"issue":"1","key":"i1543-2165-138-9-1186-b19","series-title":"Clin Cancer Res","first-page":"160","article-title":"Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia","volume":"9","author":"Kantarjian\n              HM,","year":"2003","unstructured":"Kantarjian\n              HM, \n            \n              Talpaz\n              M, \n            \n              Cortes\n              J, \n            et al\n          . Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia. Clin Cancer Res. 2003;9(1):160\u2013166."},{"issue":"3","key":"i1543-2165-138-9-1186-b20","series-title":"Br J Haematol","first-page":"771","article-title":"Serial monitoring of BCR-ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia","volume":"118","author":"Wang\n              L,","year":"2002","unstructured":"Wang\n              L, \n            \n              Pearson\n              K, \n            \n              Pillitteri\n              L, \n            \n              Ferguson\n              JE, \n            \n              Clark\n              RE. \n          \n          Serial monitoring of BCR-ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia. Br J Haematol. 2002;118(3):771\u2013777."},{"issue":"28","key":"i1543-2165-138-9-1186-b21","series-title":"J Clin Oncol","first-page":"4754","article-title":"High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses","volume":"27","author":"Cortes\n              JE,","year":"2009","unstructured":"Cortes\n              JE, \n            \n              Kantarjian\n              HM, \n            \n              Goldberg\n              SL, \n            et al\n          . High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses. J Clin Oncol. 2009;27(28):4754\u20134759."},{"issue":"12","key":"i1543-2165-138-9-1186-b22","series-title":"Blood","first-page":"4437","article-title":"European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor","volume":"112","author":"Marin\n              D,","year":"2008","unstructured":"Marin\n              D, \n            \n              Milojkovic\n              D, \n            \n              Olavarria\n              E, \n            et al\n          . European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood. 2008;112(12):4437\u20134444."},{"issue":"25","key":"i1543-2165-138-9-1186-b23","series-title":"Blood","first-page":"6315","article-title":"Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy","volume":"113","author":"Quintas-Cardama\n              A,","year":"2009","unstructured":"Quintas-Cardama\n              A, \n            \n              Kantarjian\n              H, \n            \n              Jones\n              D, \n            et al\n          . Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy. Blood. 2009;113(25):6315\u20136321."},{"key":"i1543-2165-138-9-1186-b01","series-title":"NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia. Version 1","year":"2014","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia. Version 1. 2014. http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cml.pdf. Accessed September 25, 2013."},{"key":"i1543-2165-138-9-1186-b02","series-title":"J Natl Cancer Inst","first-page":"85","article-title":"Chromosome studies on normal and leukemic human leukocytes","volume":"25","author":"Nowell\n              PC,","year":"1960","unstructured":"Nowell\n              PC, \n            \n              Hungerford\n              DA. \n          \n          Chromosome studies on normal and leukemic human leukocytes. J Natl Cancer Inst. 1960;25:85\u2013109."},{"key":"i1543-2165-138-9-1186-b03","series-title":"Gleevec (imatinib mesylate) [US prescribing information]","year":"2012","unstructured":"Gleevec (imatinib mesylate) [US prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2012."},{"key":"i1543-2165-138-9-1186-b04","series-title":"Tasigna (nilotinib) [US prescribing information]","year":"2012","unstructured":"Tasigna (nilotinib) [US prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2012."},{"key":"i1543-2165-138-9-1186-b05","series-title":"Sprycel (dasatinib) [US prescribing information]","year":"2011","unstructured":"Sprycel (dasatinib) [US prescribing information]. Princeton, NJ: Bristol Meyers Squibb Company; 2011."},{"key":"i1543-2165-138-9-1186-b06","series-title":"Bosulif (bosutinib) [prescribing information]","year":"2012","unstructured":"Bosulif (bosutinib) [prescribing information]. New York, NY: Pfizer Labs; 2012."},{"key":"i1543-2165-138-9-1186-b07","series-title":"Iclusig (ponatinib) [prescribing information]","year":"2012","unstructured":"Iclusig (ponatinib) [prescribing information]. Cambridge, MA: ARIAD Pharmaceuticals, Inc; 2012."},{"issue":"12","key":"i1543-2165-138-9-1186-b08","series-title":"Leukemia","first-page":"2401","article-title":"Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase","volume":"17","author":"Branford\n              S,","year":"2003","unstructured":"Branford\n              S, \n            \n              Rudzki\n              Z, \n            \n              Harper\n              A, \n            et al\n          . Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Leukemia. 2003;17(12):2401\u20132409."},{"issue":"21","key":"i1543-2165-138-9-1186-b09","series-title":"Blood (ASH Annu Meet Abstr)","first-page":"69","article-title":"Assessment of early molecular response as a predictor of long-term clinical outcomes in the phase 3 BELA study","volume":"120","author":"Brummendorf\n              TH,","year":"2012","unstructured":"Brummendorf\n              TH, \n            \n              Kantarjian\n              HM, \n            \n              Gambacorti-Passerini\n              C, \n            et al\n          . Assessment of early molecular response as a predictor of long-term clinical outcomes in the phase 3 BELA study. Blood (ASH Annu Meet Abstr). 2012;120(21):69."},{"issue":"9","key":"i1543-2165-138-9-1186-b10","series-title":"Leukemia","first-page":"2096","article-title":"Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)","volume":"26","author":"Hanfstein\n              B,","year":"2012","unstructured":"Hanfstein\n              B, \n            \n              Muller\n              MC, \n            \n              Hehlmann\n              R, \n            et al\n          . Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia. 2012;26(9):2096\u20132102."},{"issue":"21","key":"i1543-2165-138-9-1186-b11","series-title":"Blood (ASH Annu Meet Abstr)","first-page":"167","article-title":"Outcome of patients with chronic myeloid leukemia in chronic phase (CML-CP) based on early molecular response and factors associated with early response: 4-year follow-up data from ENESTND (Evaluating Nilotinib Efficacy and Safety in Clinical Trials Newly Diagnosed Patients)","volume":"120","author":"Hochhaus\n              A,","year":"2012","unstructured":"Hochhaus\n              A, \n            \n              Hughes\n              TP, \n            \n              Saglio\n              G, \n            et al\n          . Outcome of patients with chronic myeloid leukemia in chronic phase (CML-CP) based on early molecular response and factors associated with early response: 4-year follow-up data from ENESTND (Evaluating Nilotinib Efficacy and Safety in Clinical Trials Newly Diagnosed Patients). Blood (ASH Annu Meet Abstr). 2012;120(21):167."},{"issue":"2","key":"i1543-2165-138-9-1186-b12","series-title":"Blood","first-page":"291","article-title":"Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib","volume":"120","author":"Marin\n              D,","year":"2012","unstructured":"Marin\n              D, \n            \n              Hedgley\n              C, \n            \n              Clark\n              RE, \n            et al\n          . Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib. Blood. 2012;120(2):291\u2013294."},{"issue":"3","key":"i1543-2165-138-9-1186-b13","series-title":"J Clin Oncol","first-page":"232","article-title":"Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors","volume":"30","author":"Marin\n              D,","year":"2012","unstructured":"Marin\n              D, \n            \n              Ibrahim\n              AR, \n            \n              Lucas\n              C, \n            et al\n          . Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol. 2012;30(3):232\u2013238."},{"issue":"6","key":"i1543-2165-138-9-1186-b14","series-title":"Blood","first-page":"872","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani\n              M,","year":"2013","unstructured":"Baccarani\n              M, \n            \n              Deininger\n              MW, \n            \n              Rosti\n              G, \n            et al\n          . European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122(6):872\u2013884."},{"issue":"7","key":"i1543-2165-138-9-1186-b15","series-title":"J Clin Oncol","first-page":"1533","article-title":"Fluorescence in situ hybridization on peripheral-blood specimens is a reliable method to evaluate cytogenetic response in chronic myeloid leukemia","volume":"18","author":"Le Gouill\n              S,","year":"2000","unstructured":"Le Gouill\n              S, \n            \n              Talmant\n              P, \n            \n              Milpied\n              N, \n            et al\n          . Fluorescence in situ hybridization on peripheral-blood specimens is a reliable method to evaluate cytogenetic response in chronic myeloid leukemia. J Clin Oncol. 2000;18(7):1533\u20131538."},{"issue":"2","key":"i1543-2165-138-9-1186-b16","series-title":"Cancer Genet Cytogenet","first-page":"79","article-title":"Correlation of three methods of measuring cytogenetic response in chronic myelocytic leukemia","volume":"137","author":"Lesser\n              ML,","year":"2002","unstructured":"Lesser\n              ML, \n            \n              Dewald\n              GW, \n            \n              Sison\n              CP, \n            \n              Silver\n              RT. \n          \n          Correlation of three methods of measuring cytogenetic response in chronic myelocytic leukemia. Cancer Genet Cytogenet. 2002;137(2):79\u201384."},{"issue":"6","key":"i1543-2165-138-9-1186-b17","series-title":"Cancer","first-page":"1245","article-title":"Peripheral blood monitoring of chronic myeloid leukemia during treatment with imatinib, second-line agents, and beyond","volume":"117","author":"Lima\n              L,","year":"2011","unstructured":"Lima\n              L, \n            \n              Bernal-Mizrachi\n              L, \n            \n              Saxe\n              D, \n            et al\n          . Peripheral blood monitoring of chronic myeloid leukemia during treatment with imatinib, second-line agents, and beyond. Cancer. 2011;117(6):1245\u20131252."},{"issue":"4","key":"i1543-2165-138-9-1186-b18","series-title":"Blood","first-page":"1549","article-title":"Quantification of residual disease in chronic myelogenous leukemia patients on interferon-alpha therapy by competitive polymerase chain reaction","volume":"87","author":"Hochhaus\n              A,","year":"1996","unstructured":"Hochhaus\n              A, \n            \n              Lin\n              F, \n            \n              Reiter\n              A, \n            et al\n          . Quantification of residual disease in chronic myelogenous leukemia patients on interferon-alpha therapy by competitive polymerase chain reaction. Blood. 1996;87(4):1549\u20131555."},{"issue":"1","key":"i1543-2165-138-9-1186-b19","series-title":"Clin Cancer Res","first-page":"160","article-title":"Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia","volume":"9","author":"Kantarjian\n              HM,","year":"2003","unstructured":"Kantarjian\n              HM, \n            \n              Talpaz\n              M, \n            \n              Cortes\n              J, \n            et al\n          . Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia. Clin Cancer Res. 2003;9(1):160\u2013166."},{"issue":"3","key":"i1543-2165-138-9-1186-b20","series-title":"Br J Haematol","first-page":"771","article-title":"Serial monitoring of BCR-ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia","volume":"118","author":"Wang\n              L,","year":"2002","unstructured":"Wang\n              L, \n            \n              Pearson\n              K, \n            \n              Pillitteri\n              L, \n            \n              Ferguson\n              JE, \n            \n              Clark\n              RE. \n          \n          Serial monitoring of BCR-ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia. Br J Haematol. 2002;118(3):771\u2013777."},{"issue":"28","key":"i1543-2165-138-9-1186-b21","series-title":"J Clin Oncol","first-page":"4754","article-title":"High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses","volume":"27","author":"Cortes\n              JE,","year":"2009","unstructured":"Cortes\n              JE, \n            \n              Kantarjian\n              HM, \n            \n              Goldberg\n              SL, \n            et al\n          . High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses. J Clin Oncol. 2009;27(28):4754\u20134759."},{"issue":"12","key":"i1543-2165-138-9-1186-b22","series-title":"Blood","first-page":"4437","article-title":"European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor","volume":"112","author":"Marin\n              D,","year":"2008","unstructured":"Marin\n              D, \n            \n              Milojkovic\n              D, \n            \n              Olavarria\n              E, \n            et al\n          . European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood. 2008;112(12):4437\u20134444."},{"issue":"25","key":"i1543-2165-138-9-1186-b23","series-title":"Blood","first-page":"6315","article-title":"Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy","volume":"113","author":"Quintas-Cardama\n              A,","year":"2009","unstructured":"Quintas-Cardama\n              A, \n            \n              Kantarjian\n              H, \n            \n              Jones\n              D, \n            et al\n          . Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy. Blood. 2009;113(25):6315\u20136321."}],"container-title":["Archives of Pathology &amp; Laboratory Medicine"],"original-title":[],"link":[{"URL":"https:\/\/aplm.kglmeridian.com\/view\/journals\/arpa\/138\/9\/article-p1186.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/aplm.kglmeridian.com\/downloadpdf\/journals\/arpa\/138\/9\/article-p1186.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aplm.kglmeridian.com\/downloadpdf\/journals\/arpa\/138\/9\/article-p1186.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T01:02:25Z","timestamp":1770771745000},"score":1,"resource":{"primary":{"URL":"https:\/\/aplm.kglmeridian.com\/view\/journals\/arpa\/138\/9\/article-p1186.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":46,"journal-issue":{"issue":"9"},"URL":"https:\/\/doi.org\/10.5858\/arpa.2013-0584-oa","relation":{},"ISSN":["1543-2165","0003-9985"],"issn-type":[{"value":"1543-2165","type":"electronic"},{"value":"0003-9985","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]}}}